Janney Capital analyst Debjit Chattopadhyay noted that Clovis (CLVS) shares are up about 41% year-to-date, citing accelerated approval for its rucaparib drug in advanced ovarian cancer, the all cash acquisition of Ariad (ARIA) and the $575M divestiture with potential for further payments of Merrimack's (MACK) Onivyde franchise as among the tailwinds driving Clovis shares higher. However, a "near-term Clovis buyout may not materialize" until key competitive readouts settle the debate on the equivalency/superiority of various PARP inhibitors, Chattopadhyay tells investors. Based on near-term uncertainties, he advises waiting for a better entry point to Clovis shares, on which he has a Neutral rating and $44 fair value estimate.